Myelodysplastic syndrome: An inability to appropriately respond to damaged DNA?

Experimental Hematology

Volumn 41, Issue 8, 2013, Pages 665-674

  Zhou, Ting ^a   Hasty, Paul ^a,b   Walter, Christi A ^a,b,c   Bishop, Alexander J R ^a,b   Scott, Linda M ^d   Rebel, Vivienne I ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; HISTONE H2AX; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL CYCLE ARREST; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; GENOMIC INSTABILITY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; MISMATCH REPAIR; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW;

ANIMALS; APOPTOSIS; DISEASE PROGRESSION; DNA DAMAGE; DNA REPAIR; GENOMIC INSTABILITY; HEMATOPOIESIS; HUMANS; MICE; MYELODYSPLASTIC SYNDROMES;

EID: 84880755300     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.008     Document Type: Review

References (108)

1. Chung Y.J., Choi C.W., Slape C., Fry T., Aplan P.D. Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. Proc Natl Acad Sci USA 2008, 105:14088-14093.
2. Nilsson L., Eden P., Olsson E., et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007, 110:3005-3014.
3. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:692-701.
4. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
5. Ma X. Epidemiology of myelodysplastic syndromes. Am J Med 2012, 125:S2-S5.
6. Barnard D.R., Woods W.G. Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer-an update. Leuk Lymphoma 2005, 46:651-663.
7. Bhatia R., Deeg H.J. Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. Curr Opin Hematol 2011, 18:77-82.
8. Elghetany M.T. Myelodysplastic syndromes in children: A critical review of issues in the diagnosis and classification of 887 cases from 13 published series. Arch Pathol Lab Med 2007, 131:1110-1116.
9. Leone G., Fianchi L., Pagano L., Voso M.T. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact 2010, 184:39-45.
10. Cioc A.M., Wagner J.E., MacMillan M.L., DeFor T., Hirsch B. Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: Morphologic and cytogenetic characteristics. Am J Clin Pathol 2010, 133:92-100.
11. Gadner H., Haas O.A. Experience in pediatric myelodysplastic syndromes. Hematol Oncol Clin North Am 1992, 6:655-672.
12. Goto M., Miller R.W., Ishikawa Y., Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 1996, 5:239-246.
13. Ilhan I., Arikan U., Buyukpamukcu M. Myelodysplastic syndromes and RTS. Pediatr Hematol Oncol 1996, 13:197.
14. Narayan S., Fleming C., Trainer A.H., Craig J.A. Rothmund-Thomson syndrome with myelodysplasia. Pediatr Dermatol 2001, 18:210-212.
15. Pianigiani E., De Aloe G., Andreassi A., Rubegni P., Fimiani M. Rothmund-Thomson syndrome (Thomson-type) and myelodysplasia. Pediatr Dermatol 2001, 18:422-425.
16. Poppe B., Van Limbergen H., Van Roy N., et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet 2001, 128:39-42.
17. Rizzari C., Bacchiocchi D., Rovelli A., et al. Myelodysplastic syndrome in a child with Rothmund-Thomson syndrome: A case report. J Pediatr Hematol Oncol 1996, 18:96-97.
18. Talwalkar S.S., Yin C.C., Naeem R.C., Hicks M.J., Strong L.C., Abruzzo L.V. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med 2010, 134:1010-1015.
19. Yamamoto K., Imakiire A., Miyagawa N., Kasahara T. A report of two cases of Werner's syndrome and review of the literature. J Orthop Surg (Hong Kong) 2003, 11:224-233.
20. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
21. Bejar R., Levine R., Ebert B.L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011, 29:504-515.
22. Davids M.S., Steensma D.P. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther 2010, 10:309-319.
23. Graubert T., Walter M.J. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011, 2011:543-549.
24. Raza A., Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012, 12:849-859.
25. Gilliland D.G. Hematologic malignancies. Curr Opin Hematol 2001, 8:189-191.
26. Nolte F., Hofmann W.K. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Annals of hematology 2008, 87:777-795.
27. Sanz G.F., Sanz M.A., Vallespi T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989, 74:395-408.
28. Lin Y.W., Slape C., Zhang Z., Aplan P.D. NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia. Blood 2005, 106:287-295.
29. Ma Y., Cui W., Yang J., et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006, 108:2726-2735.
30. Watanabe-Okochi N., Kitaura J., Ono R., et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008, 111:4297-4308.
31. Wu M.Y., Eldin K.W., Beaudet A.L. Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes. J Natl Cancer Inst 2008, 100:1247-1259.
32. Zimmer S.N., Lemieux M.E., Karia B.P., et al. Mice heterozygous for CREB binding protein are hypersensitive to gamma-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm. Exp Hematol 2012, 40:295-306.e295.
33. Slape C., Hartung H., Lin Y.W., Bies J., Wolff L., Aplan P.D. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res 2007, 67:5148-5155.
34. Slape C., Liu L.Y., Beachy S., Aplan P.D. Leukemic transformation in mice expressing a NUP98-HOXD13 transgene is accompanied by spontaneous mutations in Nras, Kras, and Cbl. Blood 2008, 112:2017-2019.
35. Nigg E.A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995, 17:471-480.
36. Callegari A.J., Kelly T.J. UV irradiation induces a postreplication DNA damage checkpoint. Proc Natl Acad Sci U S A 2006, 103:15877-15882.
37. Duensing A., Teng X., Liu Y., Tseng M., Spardy N., Duensing S. A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress. J Cell Biochem 2006, 99:759-769.
38. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91:2985-2990.
39. Uchida T., Kinoshita T., Nagai H., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997, 90:1403-1409.
40. Ribeiro H.L., De Oliveira R.T., Maia A.R., et al. ATM polymorphism is associated with low risk myelodysplastic syndrome. DNA Repair (Amst) 2013, 12:87-89.
41. Almeida K.H., Sobol R.W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst) 2007, 6:695-711.
42. Dimri G.P., Testori A., Acosta M., Campisi J. Replicative senescence, aging and growth-regulatory transcription factors. Biol Signals 1996, 5:154-162.
43. Hitomi K., Iwai S., Tainer J.A. The intricate structural chemistry of base excision repair machinery: implications for DNA damage recognition, removal, and repair. DNA Repair (Amst) 2007, 6:410-428.
44. Jankowska A.M., Gondek L.P., Szpurka H., Nearman Z.P., Tiu R.V., Maciejewski J.P. Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome. Leukemia 2008, 22:551-558.
45. Novotna B., Bagryantseva Y., Siskova M., Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome. Leuk Res 2009, 33:340-343.
46. Peddie C.M., Wolf C.R., McLellan L.I., Collins A.R., Bowen D.T. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997, 99:625-631.
47. Kasparek T.R., Humphrey T.C. DNA double-strand break repair pathways, chromosomal rearrangements and cancer. Semin Cell Dev Biol 2011, 22:886-897.
48. Burma S., Chen B.P., Chen D.J. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 2006, 5:1042-1048.
49. McVey M., Lee S.E. MMEJ repair of double-strand breaks (director's cut): Deleted sequences and alternative endings. Trends Genetics 2008, 24:529-538.
50. Omidvar N., Kogan S., Beurlet S., et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res 2007, 67:11657-11667.
51. Rassool F.V., Gaymes T.J., Omidvar N., et al. Reactive oxygen species, DNA damage, and error-prone repair: A model for genomic instability with progression in myeloid leukemia?. Cancer Res 2007, 67:8762-8771.
52. Puthiyaveetil A.G., Reilly C.M., Pardee T.S., Caudell D.L. Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Leuk Res 2013, 37:112-116.
53. Puthiyaveetil A.G., Heid B., Reilly C.M., HogenEsch H., Caudell D.L. A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production. Exp Hematol 2012, 40:622-633.
54. Buermeyer A.B., Deschenes S.M., Baker S.M., Liskay R.M. Mammalian DNA mismatch repair. Annu Rev Genet 1999, 33:533-564.
55. Alemayehu A., Fridrichova I. The MRE11/RAD50/NBS1 complex destabilization in Lynch-syndrome patients. Eur J Human Genet 2007, 15:922-929.
56. Ben-Yehuda D., Krichevsky S., Caspi O., et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996, 88:4296-4303.
57. Casorelli I., Offman J., Mele L., et al. Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. DNA Repair (Amst) 2003, 2:547-559.
58. Olipitz W., Hopfinger G., Aguiar R.C., et al. Defective DNA-mismatch repair: a potential mediator of leukemogenic susceptibility in therapy-related myelodysplasia and leukemia. Genes Chromosomes Cancer 2002, 34:243-248.
59. Reese J.S., Liu L., Gerson S.L. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 2003, 102:1626-1633.
60. Kamileri I., Karakasilioti I., Garinis G.A. Nucleotide excision repair: new tricks with old bricks. Trends Genetics 2012, 28:566-573.
61. Kuramoto K., Ban S., Oda K., Tanaka H., Kimura A., Suzuki G. Chromosomal instability and radiosensitivity in myelodysplastic syndrome cells. Leukemia 2002, 16:2253-2258.
62. Carney D.A., Westerman D.A., Tam C.S., et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 2010, 24:2056-2062.
63. Tam C.S., Seymour J.F., Prince H.M., et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006, 91:1546-1550.
64. Parker J.E., Mufti G.J., Rasool F., Mijovic A., Devereux S., Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938.
65. Tehranchi R., Fadeel B., Forsblom A.M., et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003, 101:1080-1086.
66. Tehranchi R., Invernizzi R., Grandien A., et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005, 106:247-253.
67. Claessens Y.E., Bouscary D., Dupont J.M., et al. Invitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002, 99:1594-1601.
68. Davis R.E., Greenberg P.L. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res 1998, 22:767-777.
69. Steensma D.P., Neiger J.D., Porcher J.C., et al. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res 2009, 69:7518-7523.
70. Wang Y.Y., Cen J.N., He J., et al. Accelerated cellular senescence in myelodysplastic syndrome. Exp Hematol 2009, 37:1310-1317.
71. Wang J., Sun Q., Morita Y., et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell 2012, 148:1001-1014.
72. Mohrin M., Bourke E., Alexander D., et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010, 7:174-185.
73. Shao L., Feng W., Lee K.J., Chen B.P., Zhou D. A sensitive and quantitative polymerase chain reaction-based cell free invitro non-homologous end joining assay for hematopoietic stem cells. PLoS One 2012, 7:e33499.
74. Milyavsky M., Gan O.I., Trottier M., et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 2010, 7:186-197.
75. Ceccaldi R., Parmar K., Mouly E., et al. Bone marrow failure in fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012, 11:36-49.
76. Bender C.F., Sikes M.L., Sullivan R., et al. Cancer predisposition and hematopoietic failure in Rad50(S/S) mice. Genes Dev 2002, 16:2237-2251.
77. Dumble M., Moore L., Chambers S.M., et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 2007, 109:1736-1742.
78. Ito K., Hirao A., Arai F., et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004, 431:997-1002.
79. Morales M., Liu Y., Laiakis E.C., Morgan W.F., Nimer S.D., Petrini J.H. DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesions. Cancer Res 2008, 68:2186-2193.
80. TeKippe M., Harrison D.E., Chen J. Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 2003, 31:521-527.
81. Zinkel S.S., Ong C.C., Ferguson D.O., et al. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 2003, 17:229-239.
82. + primitive hematopoietic cells and shows reduced reconstruction ability. Exp Hematol 1999, 27:1667-1674.
83. Chen M., Tomkins D.J., Auerbach W., et al. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996, 12:448-451.
84. Haneline L.S., Gobbett T.A., Ramani R., et al. Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood 1999, 94:1-8.
85. Lucas D., Escudero B., Ligos J.M., et al. Altered hematopoiesis in mice lacking DNA polymerase mu is due to inefficient double-strand break repair. PLoS Genet 2009, 5:e1000389.
86. Navarro S., Meza N.W., Quintana-Bustamante O., et al. Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1. Mol Ther 2006, 14:525-535.
87. Nijnik A., Woodbine L., Marchetti C., et al. DNA repair is limiting for haematopoietic stem cells during ageing. Nature 2007, 447:686-690.
88. Parmar K., Kim J., Sykes S.M., et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells 2010, 28:1186-1195.
89. Prasher J.M., Lalai A.S., Heijmans-Antonissen C., et al. Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1-/- mice. EMBO J 2005, 24:861-871.
90. Rossi D.J., Bryder D., Seita J., Nussenzweig A., Hoeijmakers J., Weissman I.L. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 2007, 447:725-729.
91. Whitney M.A., Royle G., Low M.J., et al. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 1996, 88:49-58.
92. Zhang S., Yajima H., Huynh H., et al. Congenital bone marrow failure in DNA-PKcs mutant mice associated with deficiencies in DNA repair. J Cell Biochem 2011, 193:295-305.
93. Holmquist G.P. Endogenous lesions, S-phase-independent spontaneous mutations, and evolutionary strategies for base excision repair. Mutat Res 1998, 400:59-68.
94. Ito K., Hirao A., Arai F., et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006, 12:446-451.
95. Tothova Z., Kollipara R., Huntly B.J., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
96. Kurimasa A., Kumano S., Boubnov N.V., et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol Cell Biol 1999, 19:3877-3884.
97. Fagbemi A.F., Orelli B., Scharer O.D. Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair (Amst) 2011, 10:722-729.
98. Steensma D.P., Tefferi A. Anemia in the elderly: How should we define it, when does it matter, and what can be done?. Mayo Clin Proc 2007, 82:958-966.
99. Damjanov I. Blood, bone marrow, and the lymphoid system. Pathophysiology 2009, 191-235. Elsevier-Saunders, Philadelphia. W. Schmidt, R. Gruliow (Eds.).
100. de Haan G., Nijhof W., Van Zant G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood 1997, 89:1543-1550.
101. Harrison D.E., Astle C.M., Stone M. Numbers and functions of transplantable primitive immunohematopoietic stem cells. Effects of age. J Immunol 1989, 142:3833-3840.
102. Kamminga L.M., van Os R., Ausema A., et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells 2005, 23:82-92.
103. Morrison S.J., Wandycz A.M., Akashi K., Globerson A., Weissman I.L. The aging of hematopoietic stem cells. Nat Med 1996, 2:1011-1016.
104. Rossi D.J., Bryder D., Zahn J.M., et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 2005, 102:9194-9199.
105. Sudo K., Ema H., Morita Y., Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J Exp Med 2000, 192:1273-1280.
106. Rube C.E., Fricke A., Widmann T.A., et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS One 2011, 6:e17487.
107. Chambers S.M., Boles N.C., Lin K.Y., et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 2007, 1:578-591.
108. Bouwman P., Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012, 12:587-598.